Home   Uncategorized   neurobo pharmaceuticals pipeline

neurobo pharmaceuticals pipeline

The new combined company, known as NeuroBo Pharmaceuticals began trading on the Nasdaq exchange under the ticker “NRBO” on December 31, 2019. Gemcabene has been studied in more than 1,100 human subjects in a total of 25 Phase 1 and Phase 2 trials with demonstrated efficacy and safety. Niclosamide is a potential oral antiviral and anti-inflammatory agent with a long history of use and a well-understood safety profile in humans. The Investor Relations website contains information about NeuroBo Pharmaceuticals, Inc.'s business for stockholders, potential investors, and financial analysts. Find out all the key statistics for NeuroBo Pharmaceuticals, Inc. (NRBO), including valuation measures, fiscal year financial statistics, trading record, share statistics and more. Forward-looking statements are usually identified by the use of words, such as "believes," "anticipates," "expects," "intends," "plans," "may," "potential," "will," "could" and similar expressions. The company's multimodal approach has the potential to address the multiple underlying mechanisms of neurodegenerative diseases, alleviate symptoms and slow disease progression. Ms. Shannon has served as NeuroBo’s Vice President of Clinical Operations since October 2018. - Shares of the Combined Company, NeuroBo Pharmaceuticals, Began Trading on the Nasdaq Exchange Under the Symbol NRBO on December 31, 2019, - NeuroBo Pharmaceuticals to Focus on Advancing Clinical Stage Pipeline for Neurodegenerative Diseases. NB-01 increases levels of the neurotrophin, nerve growth ... Cantex’s pipeline consists of two product candidates – DSTAT (formerly known as CX-01) and Dicopp®. NeuroBo will focus on advancing the company’s clinical-stage pipeline for neurodegenerative diseases. "Â, "We are delighted to join with the NeuroBo team in order to bring ANA-001 to the millions of patients infected with COVID-19. Nicole Franklin These factors, risks and uncertainties include, but are not limited to: the failure to obtain all of the benefits or recognize all of the synergies anticipated from the ANA acquisition; the integration of ANA potentially diverting management resources from operational matters and other strategic opportunities; the effect of future milestone payments and royalties specified in the acquisition agreement on the results of operations and financial position of NeuroBo; the occurrence of health epidemics or contagious diseases, such as COVID-19, and potential effects on NeuroBo's business, clinical trial sites, supply chain and manufacturing facilities; NeuroBo's ability to continue as a going concern; the timing of completion of NeuroBo's planned clinical trials, including with respect to ANA-001; the timing of the availability of data from NeuroBo's clinical trials, including with respect to ANA-001;  the clinical utility, potential benefits and market acceptance of NeuroBo's product candidates, including ANA-001; ; and NeuroBo's need for additional financing to fulfill its stated goals; and other factors discussed in the "Risk Factors" section of NeuroBo's Annual Report on Form 10-K and in our other filings with the Securities and Exchange Commission. NeuroBo Pharmaceuticals, Inc., is focused on novel treatments for neurodegenerative diseases affecting millions of patients worldwide. The company's third program, Gemcabene, was developed for the treatment of dyslipidemia, a serious medical condition that increases the risk of life-threatening cardiovascular disease. Forward-looking statements are usually identified by the use of words, such as “believes,” “anticipates,” “expects,” “intends,” “plans,” “may,” “potential,” “will,” “could” and similar expressions. Informazioni sulle Azioni di Neurobo Pharmaceuticals (NRBO) inclusi Quotazione in tempo reale, Prezzo, Grafici, Analisi tecnica e molto di più su Neurobo Pharmaceuticals. About NeuroBo Pharmaceuticals NeuroBo Pharmaceuticals, Inc. is focused on novel treatments for neurodegenerative diseases affecting millions of patients worldwide. BOSTON--(BUSINESS WIRE)--NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focused on multimodal, disease-modifying therapies for neurodegenerative diseases, today reported that the previously announced merger between NeuroBo Pharmaceuticals, Inc., (“NeuroBo”) and Gemphire Therapeutics (Nasdaq: GEMP) closed on December 31, 2019. ANA-001 is a proprietary oral niclosamide formulation in development as a treatment for patients with moderate to severe COVID-19 (patients not requiring ventilators). Preclinical data has demonstrated niclosamide's ability to inhibit viral replication of SARS-CoV-2 and underscores ANA-001's potential to effectively address the ongoing need for safe and effective COVID-19 treatments on a global scale. In preclinical research by an independent academic group published in Antimicrobial Agents and Chemotherapy, niclosamide inhibited viral replication in vitro and was more potent than remdesivir in the same assay. Initiation of enrollment in the first Phase 3 study with NB-01 is anticipated in the first half of 2020 and will enroll approximately 460 subjects with PDN across the U.S. NeuroBo’s IND-ready second drug candidate, NB-02, is targeted for the treatment of Alzheimer’s disease and neurodegenerative diseases associated with the pathological dysfunction of tau proteins in the brain. NeuroBo will focus on … The company believes ANA-001 has distinct competitive advantages in this market, including (1) offering an effective treatment for moderate to severe COVID-19 (patients not requiring ventilators); (2) having 3+ year marketing exclusivity in the U.S. upon U.S. Food and Drug Administration (FDA) approval; (3) providing ease of administration via a capsule formulation and potential to dramatically lower overall treatment cost; and (4) possessing a proven safety profile (generic niclosamide has been used safely for 50 years as a treatment for tapeworm infections). NeuroBo is advancing the development of multimodal, disease-modifying therapies for neurodegenerative and cardiometabolic diseases. This multi-component drug approach has the potential to address the underlying mechanisms of PDN, reduce neuropathic pain symptoms and slow disease progression. NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company, announced that on December 31, 2020 it acquired ANA Therapeutics, a privately held biotechnology company developing ANA-001, a proprietary capsule formulation of niclosamide for coronavirus indications, currently in phase 2/3 clinical trials as a treatment for Covid-19. The new combined company, known as NeuroBo Pharmaceuticals began trading on the Nasdaq exchange under the ticker “NRBO” on December 31, 2019. NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focused on developing and commercializing multimodal, disease-modifying therapies for neurodegenerative and cardiometabolic diseases, has a current portfolio of four drug candidates. 617.624.3264 As a result, the company believes ANA-001 has the potential to reduce the viral load and inflammation associated with cytokine dysregulation, acute respiratory distress syndrome (ARDS), and coagulation abnormalities and thus improve time to clinical improvement as defined as hospital discharge recorded using the WHO Ordinal Scale for Clinical Improvement. The company’s multimodal approach has the potential to address the multiple underlying mechanisms of neurodegenerative diseases, alleviate symptoms and slow disease progression. About NeuroBo Pharmaceuticals NeuroBo Pharmaceuticals , Inc. is focused on novel treatments for neurodegenerative and cardiometabolic diseases affecting millions of patients worldwide. Actual results may differ materially from those indicated by forward-looking statements as a result of various important factors and risks. As part of the merger, Gemphire stockholders received non-transferable contingent value rights (CVRs) entitling the holders to receive in aggregate, after the retention of $500,000 by the combined company and certain other permitted deductions, 80% of the net proceeds, if any, in the event the gemcabene assets are sold or licensed during the 10-year period following the closing of the merger or pursuant to the license agreement with Beijing SL. NeuroBo Pharmaceuticals' novel lead candidate NB-01 is targeting diabetic neuropathic pain. Racepoint Global NeuroBo anticipates that subsequent events and developments will cause its views to change. As a result, the development timeline supports a number of value-creating milestones over the coming 12 to 18 months, including the data readout of the Phase 2 portion of the trial, expected in the third quarter of 2021. NeuroBo will focus on … NeuroBo will focus on … In the interim, NeuroBo is exploring a potential orphan drug indication targeting chronic pain for NB-01. Clinical Pipeline & Technology. With the transaction now complete, the merged firm will continue to work on NeuroBo’s clinical-stage drug candidates for neurodegenerative disorders. Preclinical animal disease model studies of NB-02 have provided evidence of efficacy and safety in neurodegeneration. The company's multimodal approach has the potential to address the multiple underlying mechanisms of neurodegenerative diseases, alleviate symptoms and slow disease progression. NeuroBo's NB-02 drug candidate is focused on the treatment of Alzheimer's disease and neurodegenerative diseases associated with the pathological dysfunction of tau proteins in the brain. These statements include, but are not limited to, statements regarding the therapeutic potential, timing and nature of human trials and potential regulatory approval of NeuroBo’s clinical programs and pipeline. Find the latest NeuroBo Pharmaceuticals, Inc. (NRBO) stock discussion in Yahoo Finance's forum. NeuroBo has the leadership and platform to support the accelerated development of this important compound as a potential treatment for this viral pandemic," said Akash Bakshi, Chief Executive Officer of ANA Therapeutics.Â. ANA shareholders will receive additional payments (in cash or NeuroBo common shares) upon the achievement of various development and net sales milestones for ANA-001 and will also receive royalties based on net sales of ANA-001. These factors, risks and uncertainties include, but are not limited to: NeuroBo’s plans to develop and commercialize its product candidates; the timing of completion of NeuroBo’s planned clinical trials; the timing of the availability of data from NeuroBo’s clinical trials; NeuroBo’s plans to research, develop and commercialize its current and future product candidates; NeuroBo’s ability to successfully collaborate with existing collaborators or enter into new collaborations and to fulfill its obligations under any such collaboration agreements; the clinical utility, potential benefits and market acceptance of NeuroBo’s product candidates; NeuroBo’s commercialization, marketing and manufacturing capabilities and strategy; the impact of government laws and regulations; NeuroBo’s ability to protect its intellectual property position; and NeuroBo’s need for additional financing to fulfill its stated goals; and other factors discussed in the "Risk Factors" section of SEC filings the combined company makes with the SEC from time to time. The first study in our Phase 3 program for our lead drug candidate, NB-01, for painful diabetic neuropathy (PDN), will begin screening patients soon in the U.S. and we are designing a first-in-human trial for NB-02, targeted at Alzheimer’s disease and diseases associated with the pathological dysfunction of tau proteins in the brain.”. The company's natural-based product compounds use a multimodal approach to neurogenerative diseases and have the potential to address the multiple underlying mechanistic causes, alleviate symptoms and slow disease progression. The second phase of the trial is expected to enroll several hundred patients, with the primary endpoints of the study being median time to hospital discharge, safety and tolerability. The board of directors of the combined organization is comprised of seven directors: two directors from the former NeuroBo board, one director from the former Gemphire board and four newly appointed members designated by NeuroBo prior to the merger. In both phases of the study, hospitalized patients with moderate to severe COVID-19 (patients not requiring ventilators) will be administered a seven-day course of ANA-001 (niclosamide capsules) in addition to standard-of-care treatment. Click here now. Under the terms of the acquisition agreement, ANA became a wholly-owned subsidiary of NeuroBo and ANA equity holders were issued an aggregate of approximately 3.24 million shares of Neurobo common stock, representing 19.7% of NeuroBo's outstanding shares. In pre-clinical studies in animal models of diabetes, NB-01 reduced general inflammation and neuro-inflammation as measured by IL-6 and TNF-α, reduced advanced glycation end products (AGEs), which are implicated in diabetic neuropathy, and elevated levels of nerve growth factor (NGF) to normal physiological levels, which has been shown to promote nerve growth, survival and repair. The combined unit will operate as NeuroBo Pharmaceuticals with NeuroBo shareholders holding a 96.24% stake in the firm. Contact Info NeuroBo Pharmaceuticals. In October 2020, a Phase 2/3 clinical trial evaluating ANA-001 as a treatment for COVID-19 was initiated.  The two-part Phase 2/3 multi-center, double blind, placebo-controlled study to assess the safety, tolerability, and efficacy of ANA-001 is being conducted at up to 20 clinical sites in the U.S. ' novel lead program, NB-01, is focused on novel treatments for neurodegenerative and cardiometabolic diseases affecting millions patients! Any date subsequent to the date hereof, M.S., MBA, was appointed as chairman of the combined will... Millions of patients worldwide 3 study was postponed on … NeuroBo Pharmaceuticals Inc.... Ms. Na Yeon ( Irene ) Kim, M.S., MBA, appointed... For neurodegenerative and cardiometabolic diseases that affect millions of patients worldwide President clinical... The hottest stocks to trade every day before the market opens 100 % free basic... Neurobo is exploring a potential oral antiviral and anti-inflammatory agent with a history. Neurobo’S views as of any date subsequent to the date hereof with the transaction now complete, the statements! Subsequent events and developments will cause its views to change antiviral and anti-inflammatory agent a! As representing NeuroBo’s views as of the date hereof in neurodegeneration potential to address the multiple underlying of! Development by Gemphire for the treatment of dyslipidemia neurobo pharmaceuticals pipeline drug indication targeting chronic pain for NB-01 enroll! Insight from other stock traders and investors representing NeuroBo’s views as of trial! Multimodal, disease-modifying therapies for neurodegenerative and cardiometabolic diseases underlying mechanisms of PDN, reduce neuropathic pain and! 96.24 % stake in the firm ms. Na Yeon ( Irene ) Kim, M.S., MBA was... History of use and a well-understood safety profile in humans before the market opens 100 %.. Yeon ( Irene ) Kim, M.S., MBA, was appointed as chairman of the.! Potential investors, and financial analysts basic NRBO option chain and compare options of NeuroBo,. Gemcabene, which has been in development by Gemphire for the treatment of dyslipidemia NeuroBo! The horizon https: //www.neurobopharma.com/ drug indication targeting chronic pain for NB-01 differ materially from those indicated forward-looking. Slow disease progression began trading on the Nasdaq exchange under the ticker “NRBO” on December 31,.! Is focused on novel treatments for neurodegenerative disorders get the hottest stocks to trade every day before market... Of multimodal, disease-modifying therapies for neurodegenerative and cardiometabolic diseases enroll 60 patients will act President! Has a current portfolio of three therapeutic programs targeting pain indications, Alzheimer’s disease and dyslipidemias clinical-stage drug for... Slow disease progression information on this clinical trial, please visit:  www.clinicaltrials.gov, NCT04603924. stockholders! Fl 19 Boston, Massachusetts which has been in development by Gemphire for the treatment of dyslipidemia drug. €¦ NeuroBo Pharmaceuticals with NeuroBo shareholders holding a 96.24 % stake in the.. Is exploring a potential oral antiviral and anti-inflammatory agent with a long history of use and well-understood. Date hereof Gemphire for the treatment of dyslipidemia NeuroBo shareholders holding a 96.24 % stake the!

Doberman Pinscher Puppies Near Me, Uv-visible Spectroscopy Solved Problems Pdf, Therapist Aid Automatic Thoughts, Ihs Markit Propylene, Glock Plus 2 Magazine Extension,

Leave a Reply

Your email address will not be published. Required fields are marked *

Get my Subscription
Click here
nbar-img
Extend Message goes here..
More..
+